Why Is CHARLES RIV LABORATO (CRL) Stock Up Today?

Charles River Laboratories International Inc. shares rose 5.59% to $292.82 on Tuesday, driven by the release of a new strategic vision at the company’s 2026 Investor Day and broader industry forecasts for growth in contract research and drug safety markets. The stock opened at $278.01 and reached an intraday high of $294.24 before settling near the session’s top. The move follows a wave of market research reports highlighting expanding opportunities in AI-enabled clinical trials and outsourcing services.

What Happened

The company outlined a refreshed strategic vision at its 2026 Investor Day, emphasizing profitable growth and long-term value creation. This event coincided with the release of a slide deck detailing its outlook and operational roadmap. Separately, multiple market research reports from the past 36 hours projected significant growth in the contract research organization and drug safety markets, with Charles River Laboratories named among key industry players. These reports highlighted AI-driven innovations, global patient recruitment, and real-world evidence as key growth drivers. The SEC also filed an 8-K on behalf of CRL, disclosing Regulation FD information and related financial statements.

What The Data Shows

The stock’s intraday session showed strong volatility, with a high of $294.24 at 9:45 AM ET and a low of $276.70 shortly after the open. Volume remained subdued at 0.0M shares, significantly below its 3-month daily average. Despite the rally, CRL remains unprofitable with a trailing twelve-month EPS of -4.88 and a net margin of -6.0%. The stock is currently trading near its 52-week high of $303.31. The 52-week tape also showed one fresh 52-week low and 12 fresh 52-week highs on September 24, suggesting a mixed but active market environment.

What To Watch

The company is expected to report FY26 revenue and non-GAAP earnings in the coming months. Investors should monitor the breadth of coverage and any follow-up analyst commentary, particularly from Evercore ISI Group, which recently raised its price target to $320.